

CITATION REPORT

List of articles citing

Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients

DOI: 10.2165/00003088-200544050-00003
Clinical Pharmacokinetics, 2005, 44, 495-507.

Source: <https://exaly.com/paper-pdf/39421286/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
102	Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. 2005 , 79, 1477-83		123
101	Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. 2005 , 77, 425-9		57
100	Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. 2005 , 65, 859-78		84
99	Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients. 2006 , 63, S17-21		5
98	Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. 2006 , 12, 635-40		55
97	Valganciclovir. 2006 , 20, 82-87		9
96	Valganciclovir for cytomegalovirus prophylaxis in liver transplant recipients. 2006 , 12, 1022-1023		3
95	Valganciclovir: what is the status in solid organ transplantation?. 2006 , 1, 147-156		5
94	Assessing the role of human recombinant hyaluronidase in gravity-driven subcutaneous hydration: the INFUSE-LR study. 2007 , 10, 1312-20		45
93	Is low-dose valganciclovir the same as appropriate-dose valganciclovir?. 2007 , 84, 126; author reply 126-7		5
92	Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. 2007 , 83, 874-82		33
91	AuthorsReply. 2007 , 84, 126-127		
90	Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients. 2007 , 39, 3266-70		11
89	Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation. 2007 , 39, 3111-6		27
88	Lung transplantation for cystic fibrosis: current concepts and one center's experience. 2007 , 6, 334-50		33
87	Determination of ganciclovir in different matrices from solid organ transplanted patients treated with a wide range of concomitant drugs. 2007 , 43, 1039-44		16
86	Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples. 2007 , 852, 420-9		39

85	Cytomegalovirus in transplantation - challenging the status quo. 2007 , 21, 149-58		212
84	Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. 2007 , 11, 187-95		70
83	Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. 2007 , 7, 2106-13		317
82	Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. 2008 , 8, 1297-302		36
81	Valganciclovir and human herpesvirus-8. 2008 , 198, 6-7		1
80	Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. 2008 , 46, 831-9		83
79	Maribavir: a new oral anti-cytomegalovirus drug. 2008 , 3, 435-443		7
78	Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. 2009 , 53, 3017-23		39
77	Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. 2009 , 53, 4816-24		39
76	Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. 2009 , 9, 636-43		85
75	A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. 2009 , 9, 2324-30		27
74	Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. 2009 , 11, 106-11		17
73	Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. 2010 , 12, 195-203		41
72	Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics. 2010 , 12, 204-12		15
71	Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 321-8	6.2	21
70	Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. <i>Clinical Pharmacokinetics</i> , 2009 , 48, 399-418	6.2	54
69	Management of Cytomegalovirus Infection After Renal Transplantation. 2009 , 17, 220-230		
68	Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days. 2010 , 90, 1414-9		14

67	Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. 2010 , 89, 320-6	45
66	Valganciclovir: recent progress. 2010 , 10, 1359-64	11
65	Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients. 2010 , 12, 657-63	7
64	Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. 2010 , 24, 794-800	12
63	Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure. 2010 , 12, 213-9	13
62	Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients. 2010 , 4, 111-9	12
61	Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. 2010 , 65, 2628-40	113
60	Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. 2010 , 67, 1417-25	50
59	Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis. 2010 , 29, 1014-20	37
58	Antiviral drugs for viruses other than human immunodeficiency virus. 2011 , 86, 1009-26	162
57	Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. 2011 , 92, 217-23	84
56	Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation. 2011 , 9, 955-65	8
55	Determination of ganciclovir in human plasma by ultra performance liquid chromatography-UV detection. 2012 , 45, 309-14	20
54	In Silico Models of Drug Metabolism and Drug Interactions. 2012 , 1	1
53	Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. 2012 , 31, 159-66	11
52	Thermus thermophilus nucleoside phosphorylases active in the synthesis of nucleoside analogues. 2012 , 78, 3128-35	22
51	Pharmacokinetics of ganciclovir and valganciclovir in the adult horse. 2013 , 36, 441-9	16
50	Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. 2013 , CD005133	37

49	Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. 2013 , CD003774	50
48	Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation. 2013 , 15, 551-8	16
47	Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity [Is there a need for maribavir?]. 2013 , 1, 829-836	
46	Optimal sparse sampling for estimating ganciclovir/valganciclovir AUC in solid organ transplant patients using NONMEN. 2014 , 36, 371-7	9
45	Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients. 2014 , 69, 500-6	19
44	Measurement of ganciclovir concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. 2014 , 427, 58-64	9
43	Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. 2014 , 78, 343-52	21
42	Antivirals against Herpes Viruses. 2015 , 546-562.e7	4
41	Pharmacokinetic studies and LC-MS/MS method development of ganciclovir and dipeptide monoester prodrugs in Sprague Dawley rats. 2015 , 40, 325-34	4
40	Construction of Metabolism Prediction Models for CYP450 3A4, 2D6, and 2C9 Based on Microsomal Metabolic Reaction System. 2016 , 17,	4
39	Site of metabolism prediction for oxidation reactions mediated by oxidoreductases based on chemical bond. 2017 , 33, 363-372	8
38	Bottom-up Meets Top-down: Complementary Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling for Regulatory Approval of a Dosing Algorithm of Valganciclovir in Very Young Children. 2016 , 100, 761-769	23
37	A Minireview: Usefulness of Transporter-Targeted Prodrugs in Enhancing Membrane Permeability. 2016 , 105, 2515-2526	23
36	Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients: a Focus on Prevention. 2016 , 18, 5	9
35	Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study. 2017 , 36, 745-750	13
34	Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients. 2017 , 15, 93-110	6
33	Low-dose valganciclovir prophylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin. 2018 , 20, e12868	4
32	Antiviral Agents. 2018 , 1551-1567.e6	3

31	Using chemical bond-based method to predict site of metabolism for five biotransformations mediated by CYP 3A4, 2D6, and 2C9. 2018 , 152, 302-314	3
30	A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients. 2018 , 32, e13369	2
29	Antiviral Therapies for Herpesviruses: Current Agents and New Directions. 2018 , 40, 1282-1298	55
28	Ganciclovir. 2018 , 43, 1-208	19
27	Pharmacokinetics and Pharmacodynamics of Antiviral Drugs in Special Population. 2019 , 977-1001	
26	Ganciclovir Therapeutic Drug Monitoring: A Case Series. 2019 , 41, 107-110	14
25	Efficacy and Safety of a Weight-based Dosing Regimen of Valganciclovir for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients. 2019 , 103, 1730-1735	6
24	Pediatric Dosing of Ganciclovir and Valganciclovir: How Model-Based Simulations Can Prevent Underexposure and Potential Treatment Failure. 2019 , 8, 167-176	11
23	Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients. 2019 , 75, 677-686	5
22	Enzyme Stabilization by Virus-Like Particles. 2020 , 59, 2870-2881	9
21	Considerations and controversies of pharmacologic management of the pediatric kidney transplant recipient. 2021 , 41, 77-102	1
20	Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients - the role of therapeutic drug monitoring. 2021 , 19, 707-718	5
19	Pharmacokinetics, Pharmacodynamics, and Therapeutic Drug Monitoring of Valganciclovir and Ganciclovir in Transplantation. 2021 ,	4
18	Cytomegalovirus Infection After Solid Organ Transplantation. 2016 , 441-475	1
17	Antiviral Drugs (Other than Antiretrovirals). 2010 , 565-610	3
16	Cytomegalovirus Infection in Transplantation. 129-167	1
15	Acyclovir in the Treatment of Herpes Viruses - A Review. 2020 , 27, 4118-4137	36
14	Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads.. 2022 , 77, 466-473	0

13	Therapeutic drug monitoring of ganciclovir: where are we?. 2021 , 44,	2
12	Antiviral Agents. 2008 , 1470-1488	
11	Vitreous implants. 2009 , 173-187	
10	Valganciclovir in pediatric organ transplantation. 2010 , 4, 147-156	
9	Antiviral Agents. 2012 , 1502-1518.e10	
8	Esophageal Infections and Disorders Associated with Acquired Immunodeficiency Syndrome. 937-948	
7	Renal transplant alfabida da doz valgansiklovir profilaksisinin etkinliĐve gĐvenilirliĐ 2020 , 45, 347-351	
6	Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis. 2014 , 19, 1185-92	7
5	Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. 2009 , 14, 697-704	69
4	Antiviral Agents. 2023 , 1583-1598.e6	0
3	Cell and tissue specific metabolism of nucleoside and nucleotide drugs: case studies and implications for precision medicine. DMD-MR-2022-000856	0
2	Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring. 1-13	0
1	Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients. 2023 ,	0